Largest acquisition for FutureLife: takeover of assisted reproduction clinics in the Netherlands

FutureLife Medical Group, one of the world’s leading providers of assisted reproduction, has acquired the Nij Group, a Dutch market leader in this field. This was noted by Hospodá?ské noviny (HN). The FutureLife Clinic is owned by the Hartenberg Holding investment fund, which is part of Prime Minister Andrej Babiš’s (ANO) trust fund. The price of the deal has not been disclosed, but it will be in the hundreds of millions, according to HN.

The Nij Group is the largest private assisted reproduction provider in the Netherlands, where it has a 10% market share, HN wrote. “It consists of three clinics: Geertgen, Linge and Barrahus,” said Jozef Janov, managing partner of Hartenberg Capital, which manages the holding’s holdings.

The FutureLife Group becomes part of a large European health group. In addition to clinics, Hartenberg Capital will also acquire Serpha’s online pharmacy for infertility drugs and Legropharma, a wholesaler.

“For us, this is the largest acquisition FutureLife has made,” added Genoa. According to him, Dutch clinics will generate sales of over half a billion kronor and EBITDA, i.e. earnings before interest, taxes, depreciation and amortization, will be 70 million kroner. The entire FutureLife group will then have a turnover of around 200 million euros, i.e. over five billion crowns. After the Spanish group IVI, FutureLife is number two on the European market.

After investing in the Netherlands, the FutureLife Group is already active in eight European countries. Own clinics in the Czech Republic, Slovakia, Great Britain, Ireland, Romania, Finland and Estonia. There are a total of 42 clinics in these countries that perform 39,000 artificial insemination cycles each year. “Thanks to us, ten thousand children are born in Europe every year. After the acquisition of Dutch clinics, it will be almost twelve thousand, ”said Janov.

Thanks to strict laws, the Czech Republic and Spain are one of the most important centers for artificial insemination in Europe. Couples pay extra for methods that increase the success of assisted reproduction. The health insurance companies only pay the basic treatment, the success rate of which is 20 percent. In the basic treatment, eggs are taken from the woman, her partner’s sperm and both are placed in a special solution. Then it only depends on the germ cells whether they come together or not.

.